Wednesday, 15 February 2017

Vivimed Labs's consolidated revenue for the quarter came in at Rs. 363 crore, registering 9.3% yoy increase. This was primarily driven by 19% yoy increase in revenue from Pharma business which accounts for 80% of company’s business.

EBITDA for the quarter rose by 68.3% yoy to Rs. 103.5 crore with a corresponding margin expansion of 999 bps. EBITDA margin for the quarter stood at 28.5%. This margin expansion was aided by 8% yoy decrease in cost of materials consumed and changes in inventories.

The PAT for the quarter came in at Rs. 51.7 crore, yoy increase of 124.8%. This was partly due to 9.8% yoy decline in finance costs.

Vivimed Labs posted Q3FY17 consolidated results on February 14.
Vivimed Labs Ltd is currently trading at Rs. 104.25, up by 7.25 points or 7.47% from its previous closing of Rs. 97 on the BSE. The scrip opened at Rs. 110 and has touched a high and low of Rs. 110.5 and Rs. 102.2 respectively. So far 3279963(NSE+BSE) shares were traded on the counter. The stock is currently trading below its 100 DMA.


For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717

0 comments: